Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record.

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

Spigel, D. R., Ervin, T. J., Ramlau, R., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Clement-Duchene, C., Barlesi, F., Govindan, R., Patel, T., Orlov, S. V., Wertheim, M. S., Zha, J., Pandita, A., Yu, W., Yauch, R. L., Patel, P. H., Peterson, A. C. · 2011 · Journal of Clinical Oncology

Abstract

7505 Background: Met is associated with a poor outcome in many cancers, including NSCLC. Met activation is a mechanism of resistance to EGFR inhibition, supporting dual inhibition of Met/EGFR. MetMAb is a monovalent monoclonal antibody that specifically binds the Met receptor. Methods: OAM4558g is a global randomized, double-blind phase II study comparing MetMAb plus erlotinib (ME) to placebo plus erlotinib (PE) in 2nd/3rd line NSCLC. Tissue collection was mandatory to assess c-Met IHC expression levels (Met Dx). Co-primary endpoints were PFS in the Met Dx+ and ITT populations. Safety and OS were additional endpoints. Following the initial unblinding, Met Dx- patients (pts) were removed from ME. Results: 128 NSCLC pts were equally randomized to receive ME or PE. 95% of tissue was evaluable for c-Met IHC, 88% for EGFR and KRAS mutations (mut), and 75% for MET FISH. Baseline characteristics were well balanced. 54% of pts had Met Dx+ NSCLC, which was associated with a worse outcome (OS HR 2.52, PE cohort). A total of 99 PFS and 70 OS events have occurred, median follow up is 9.9mos. In the Met Dx+ group, ME resulted in a statistically and clinically significant improvement in both PFS and OS. An OS benefit from ME was observed in MET FISH+ NSCLC as well as in FISH-/IHC+; removing pts with EGFR mut did not alter results. Selective benefit of ME was not observed in other subgroups. E-related toxicities were comparable between treatment arms. Conclusions: Met Dx+ NSCLC represented more than half the population and was associated with a worse outcome. The addition of M to E in these pts significantly improved PFS and OS, resulting in a near 3-fold reduction in the risk of death. This benefit was not exclusive to EGFR mut or MET FISH+ and was observed in FISH-/IHC+ pts suggesting IHC is a more sensitive predictor of benefit from MetMAb. Median (mo) Population N PFS HR OS HR PE ME 95% CI P c-Met IHC+ 65 0.47 1.5 3.0 0.26–0.85 0.01 0.37 4.6 12.6 0.20–0.71 0.002 MET FISH+ (≥5 copies) 19 0.47 2.4 12.6 0.15–1.49 0.19 FISH-/IHC+ 37 0.44 3.6 7.1 0.17–1.15 0.09 FISH-/IHC+/EGFR wt 32 0.59 3.6 7.1 0.22–1.59 0.29 c-Met IHC-* 56 3.02 9.2 5.5 1.13–8.11 0.021 ITT* 128 1.09 8.2 7.1 0.62–1.91 0.76 * Initial data cut.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.29.15_suppl.7505

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 193

Metadata

Authors
Spigel, D. R., Ervin, T. J., Ramlau, R., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Clement-Duchene, C., Barlesi, F., Govindan, R., Patel, T., Orlov, S. V., Wertheim, M. S., Zha, J., Pandita, A., Yu, W., Yauch, R. L., Patel, P. H., & Peterson, A. C.
Venue
Journal of Clinical Oncology
Published
2011-05-20
Volume
29
Issue
15_suppl
Pages
7505-7505
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2219581640
Cited by
193
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.7505
The paper
Spigel, D. R., Ervin, T. J., Ramlau, R., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Clement-Duchene, C., Barlesi, F., Govindan, R., Patel, T., Orlov, S. V., Wertheim, M. S., Zha, J., Pandita, A., Yu, W., Yauch, R. L., Patel, P. H., & Peterson, A. C. (2011). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.7505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.